Theta Burst Stimulation for Depression

This trial explores how accelerated intermittent Theta Burst Stimulation (iTBS), a type of brain stimulation therapy, can help people with major depressive disorder (MDD). The main goal is to understand how this treatment changes the brain and improves depression symptoms using advanced brain imaging techniques. Individuals diagnosed with MDD, who have tried at least one antidepressant without success, and have maintained a stable treatment plan for at least four weeks, might be suitable candidates for this study. As an unphased trial, this study offers a unique opportunity to contribute to groundbreaking research and potentially benefit from innovative treatment.

You need to have a stable treatment regimen for at least four weeks before joining the study, which means no changes to your current medications during that time. However, you cannot use benzodiazepines or lithium, but other stable psychotropic medications are allowed.

Previous studies have shown that intermittent Theta Burst Stimulation (iTBS) is safe for people with major depressive disorder (MDD). Research indicates that iTBS can quickly and safely improve depression symptoms. One study found that both the regular and faster versions of iTBS were well-tolerated by patients, with no major safety issues. Another study found that daily iTBS was as safe as another common treatment, cTBS.

Unlike traditional depression treatments like antidepressant medications and psychotherapy, accelerated intermittent Theta Burst Stimulation (iTBS) offers a novel approach by using magnetic pulses to stimulate certain brain areas. Researchers are excited because iTBS targets brain circuits directly involved in mood regulation, potentially providing quicker symptom relief. Additionally, this method could enhance synaptic density and improve functional connectivity in the brain, which might lead to more durable improvements in depression symptoms.

Research has shown that accelerated intermittent Theta Burst Stimulation (iTBS), which participants in this trial will receive, can help individuals with major depressive disorder (MDD). Studies have found that iTBS can quickly and safely reduce depression symptoms. For instance, one study found that 69.2% of patients responded well to the treatment, and 46.2% experienced complete relief from symptoms four weeks after treatment. Another study showed that depression scores dropped by 54.7% in the iTBS group, compared to a 31.87% drop in a group that received a placebo treatment. These results suggest that iTBS is a promising option for easing depression symptoms.¹³⁴⁶⁷